Different tocolytics appear equally safe long-term but we need both higher follow-up rates, and placebo-controlled trials in future.

Different tocolytics appear equally safe long-term but we need both higher follow-up rates, and placebo-controlled trials in future. BJOG. 2020 Mar 29;: Authors: Thornton JG Abstract Premature birth is not only the commonest cause of new-born babies dying, but also an important cause of long-term handicap. This is why the paper by van Winden et al. in this issue, reporting two-year outcomes for participants in their APOSTEL-3 trial, comparing atosiban with nifedipine tocolysis, is so important. PMID: 32223008 [PubMed - as supplied by publisher]
Source: BJOG : An International Journal of Obstetrics and Gynaecology - Category: OBGYN Authors: Tags: BJOG Source Type: research